Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2-specific hammerhead ribozyme.
The c-erbB-2/neu-encoded protein p185 is closely related to the growth and metastasis of adenocarcinoma. We sought to reverse the malignant phenotype of gastric cancer cell line SGC7901 with c-erbB-2-specific ribozyme. We designed the ribozyme and generated the in vitro transcription vectors of the ribozyme and its substrate. In vitro cleavage reaction indicated that the ribozyme catalyzed 79.3% target RNA in 1 hour at 37 degrees C. Then, we generated the eucaryotic expression vectors of the ribozyme and transfected them into SGC7901 cells, which highly express p185. Analyses showed that the c-erbB-2 mRNA and p185 were reduced remarkably in the ribozyme-transfected cells. The growth rate of the ribozyme-transfected cells was much lower than that of the control group. Tumorigenicity was also decreased dramatically in nude mice. The results demonstrated that c-erbB-2-specific ribozyme may inhibit the malignancy of gastric cancer cells SGC7901.
Bi
F
F
Institute of Digestive Diseases, Xijing Hospital, Xian 710032, People's Republic of China. fengbi@mailfmmu.edu.cn
Fan
D
D
Hui
H
H
Wang
C
C
Zhang
X
X
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D000818:Animals; D001483:Base Sequence; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008969:Molecular Sequence Data; D010641:Phenotype; D010957:Plasmids; D016372:RNA, Antisense / Q000627:therapeutic use*; D016337:RNA, Catalytic / Q000235:genetics / Q000627:therapeutic use*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000378:metabolism; D013274:Stomach Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D014162:Transfection; D014407:Tumor Cells, Cultured
D016372:RNA, Antisense; D016337:RNA, Catalytic; D012333:RNA, Messenger; C427204:hammerhead ribozyme